<DOC>
	<DOC>NCT02246894</DOC>
	<brief_summary>The main objectives of this study are: - to assess Optivate速 consumption (IU/kg consumed per month for prophylactic and on-demand therapy and dose at each bleed). - to assess clinical outcome when treating a bleed with Optivate速. - to evaluate Optivate速 in terms of clinical tolerance and safety in children under the age of 6 years. . - to assess FVIII inhibitor development during the study.</brief_summary>
	<brief_title>A Study to Investigate the Safety and Efficacy of Optivate速 in Children Under 6 Years of Age With Haemophilia A.</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Children under the age of 6 years with a diagnosis of severe Haemophilia A. Subjects who required FVIII therapy and did not demonstrate inhibitors to FVIII. Children with history of inhibitors to FVIII or clinically significant renal or liver disease were not eligible to participate in the study.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>